Cardiac calcium handling on trial: targeting the failing cardiomyocyte signalosome.
Cardiac calcium handling on trial: targeting the failing cardiomyocyte signalosome.
复制标题
心脏钙处理试验：针对衰竭的心肌细胞信号体。
DOI：
10.1161/circresaha.113.302748
复制
发表时间：
2014
影响因子：
20.1
通讯作者：
Most,Patrick
中科院分区：
文献类型：
--
作者：
Pleger,SvenT;Raake,Philip;Katus,HugoA;Most,Patrick
图.钙（Ca）2+对心肌细胞功能的调节不仅限于收缩性能，还扩展到对核转录、电活动、细胞存活和能量代谢的控制。使用基于重组腺相关病毒的DNA治疗制剂靶向衰竭心肌细胞内有缺陷的Ca2+信号体的关键组分，有望实现持续的治疗效果，而不仅仅是改善心脏性能。
Figure. Calcium (Ca) 2+ regulation of cardiomyocyte function is not limited to contractile performance but extends to control over nuclear transcription, electric activity, cell survival, and energy metabolism. Targeting key components of the defective Ca2+ signalosome inside failing cardiomyocytes using recombinant adeno-associated viral–based therapeutic formulations of DNA bears the promise to achieve sustained therapeutic efficacy beyond improvement of cardiac performance.